Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients
Early in the COVID-19 pandemic, it was recognized that infection with SARS-CoV-2 is associated with increased morbidity and mortality in patients with cancer; therefore, preventive vaccination in cancer survivors is expected to be particularly impactful. Heterogeneity in how a neoplastic disease dia...
Main Author: | Anastasios Dimou |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/12/2117 |
Similar Items
-
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
by: Haya Altawalah
Published: (2021-08-01) -
Humoral and adaptive immune responses to the SARS-CoV-2 vaccine
by: Roberta Rizzo, et al.
Published: (2022-09-01) -
Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination
by: Faustine Montmaneix-Engels, et al.
Published: (2024-04-01) -
Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses
by: Daniel J. Salamango
Published: (2024-04-01) -
Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)
by: Melika Ben Ahmed, et al.
Published: (2022-07-01)